Mental Health DailyResearch. Evidence. Perspective.Published research on Psychosis.
First-generation antipsychotic (FGA) shortages are not just pharmacy annoyances; they force medication changes in people who may have taken years to stabilize on a tolerable regimen. Researc…
Read articlePatients with schizophrenia have substantially elevated dementia risk compared to the general population — roughly 2-3 times the age-adjusted rate — but the specific drivers within the schiz…
Read articleClozapine is the only medication with proven efficacy for treatment-resistant schizophrenia, yet most eligible patients wait years before starting it. A 2026 paper by Perfalk and colleagues …
Read articleLurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysi…
Read articleThe dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story, and most of its supporting evidence has been cross-sectional. A 2026 longitudinal PET study by Schu…
Read articleBlack Americans are diagnosed with schizophrenia-spectrum disorders at 2.42 times the rate of White Americans, and they also score higher on negative-symptom measures than White patients car…
Read articlePsychosis is one of 19 neuropsychiatric syndromes the American College of Rheumatology recognizes as attributable to systemic lupus erythematosus (SLE), an autoimmune disease that disproport…
Read article
